能谱CT容积碘含量对晚期胃癌化疗效果的评价

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1567 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore parameters for the objective evaluation and prediction of chemotherapy efficiency by characterizing the imaging parameters of dual-energy CT scanning before and after chemotherapy in patients with advanced gastric cancer. Methods: Fifty-two patients with advanced gastric cancer confirmed by gastroscopy and pathology were collected consecutively. Dual-energy enhanced CT scanning was performed before and after chemotherapy to obtain the morphological and functional parameters of the tumors, including maximum diameter, maximum thickness, maximum cross-sectional area, volume, standardized iodine value in both artery and venous phases and volume iodine content. The changes of each parameter were also calculated. According to RECIST1.1 criteria, patients were divided into chemotherapy effective group and chemotherapy ineffective group. Mann-whitney U was used to compare parameters. Results: After chemotherapy, all values of the parameters in the chemotherapy effective group were significantly decreased (P<0.05), with the change of volume iodine content in artery and venous phase being the most significant. Changes in maximum thickness, maximum cross-sectional area, volume and iodine content in artery and venous phases in chemotherapy effective group were significantly higher than those in the ineffective group (P<0.01). Before chemotherapy, the maximum thickness in the effective group was significantly higher than that in the ineffective group (P=0.036). Conclusion: The changes of volume iodine content in venous phase by dual-energy CT might be a new parameter for the evaluation of chemotherapy efficiency, and together with morphological parameters, it may provide an accurate prediction for the chemotherapy effect on the advanced gastric cancer.

Key words： dual-energy tomography, X-ray computed volumetric iodine content advanced gastric cancer chemotherapy efficiency

Received: 02 June 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Lifang
	FU Gangze
	HUANG Dingpin
	MAN Yi
	JIN Yin
	DONG Qiantong
	HUANG Yingbao
	CHEN Yongchun
	WANG Hongqing

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I12/898

[1] 王芳, 高剑波, 梁盼. CT能谱曲线及碘含量测定在早期胃癌诊断中的应用价值[J]. 中华胃肠外科杂志, 2015, 18(3): 243-247.
[2] 邢静静, 柴亚如, 高剑波, 等. 能谱CT在鉴别T3及T4a期胃癌中的应用价值[J]. 中华胃肠外科杂志, 2016, 19(5): 580-584.
[3] CHEN L, DUAN Q, XUE Y, et al. Spectral CT characterizing the pathological type of gastric cancer[J]. Chin J Radiol, 2013, 47(7): 634-637.
[4] TANG L, LI Z Y, LI Z W, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression[J]. Clin Radiol, 2015, 70(11): 1198-1204.
[5] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45 (2): 228-247.
[6] CRABB S J, PATSIOS D, SAUERBREI E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(3): 404-410.
[7] ZHANG D, LI X, LIU B. Objective characterization of GE discovery CT750 HD scanner: gemstone spectral imaging mode[J]. Med Phys, 2011, 38(3): 1178-1188.
[8] DE CECCO C N, DARNELL A, RENGO M, et al. Dual-energy CT: oncologic applications[J]. AJR Am J Roentgenol, 2012, 199(5 Suppl): S98-S105.
[9] KIM Y N, LEE H Y, LEE K S, et al. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?[J]. Korean J Radiol, 2012, 13(6): 702-710.
[10] APFALTRER P, MEYER M, MEIER C, et al. Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor re-sponse?[J]. Invest Radiol, 2012, 47(1): 65-70.
[11] HORGER M, LAUER U M, SCHRAML C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib[J]. BMC Cancer, 2009, 9: 208.
[12] JIANG T, KAMBADAKONE A, KULKAMI N M, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)[J]. Invest Radiol, 2012, 47(1): 11-17.
[13] LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.